Donacom

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Donacom

Quick Facts

Property Description
Active ingredient Glucosamine sulfate
Form Tablet, capsule, or powder for oral solution
Pharmacological class Chondroprotector / SYSADOA
General purpose Structural support for joints in degenerative joint disease
Origin Derived from an endogenous compound (amino sugar)

What Type of Medicine is Donacom?

Donacom is classified as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA) and fundamentally functions as a Chondroprotector. This classification emphasizes the medicine's role in supporting the structure of the joint over providing immediate pain relief, setting it apart from typical analgesics. Its active substance, Glucosamine, is an amino sugar and an endogenous compound that naturally occurs in human cartilage, defining the product as a structural agent for degenerative joint disease. Glucosamine is a compound found naturally in the body, primarily in cartilage, and its properties are characterized by specific pharmacological actions. The drug is often available over-the-counter (OTC), reflecting its generally favorable safety profile for long-term use in the management of joint discomfort.


Composition and Pharmaceutical Form

The medicine is a monocomponent preparation containing Glucosamine sulfate as its single primary active ingredient. Although Glucosamine is a natural constituent of cartilage matrix, the pharmaceutical grade of Glucosamine sulfate is typically synthetically or semi-synthetically derived for purity and standardization. Donacom is designed for oral administration and is available in various drug forms, including hard tablets, sealed capsules, or a powder designed to be prepared as an oral solution. The availability of multiple forms makes it a versatile option for the adults and elderly population who may have specific administration preferences.


General Purpose of Glucosamine Therapy

The general purpose of this therapy is to structurally address degenerative joint disease by supporting the cartilage matrix synthesis within affected joints. Glucosamine serves as an essential building block, aiding the production of proteoglycans and concurrently exhibiting anti-catabolic activity that helps slow down the enzymatic degradation of existing cartilage. Glucosamine, particularly the sulfate form, is utilized for the long-term management of joint discomfort. This supportive physiological action is intended to offer long-term structural modulation of the joint, contributing to sustained relief from joint pain and stiffness.

Regulatory References

  1. NIH Glucosamine Overview

What side effects are possible with Donacom?

Possible Side Effects and Safety Information

The safety profile for Donacom (Glucosamine Sulfate) is based on clinical data that documents adverse reactions primarily affecting the gastrointestinal tract and the nervous system.

Adverse Reactions by Frequency

Classification System-Organ Class Examples of Reactions
Common (ge 1/100 to < 1/10) Gastrointestinal Disorders Nausea, Abdominal Pain, Indigestion, Diarrhea, Constipation, Flatulence
Nervous System Disorders Headache, Somnolence (sleepiness), Tiredness
Uncommon (ge 1/1,000 to < 1/100) Skin and Subcutaneous Tissue Disorders Redness of the Skin (Erythema), Itching (Pruritus), Flushing, Skin Inflammation (Cutaneous Rashes)
Not Known (Cannot be estimated) Immune System Disorders Allergic Reaction, Angioedema, Hives
Nervous System Disorders Dizziness, Insomnia, Visual Disturbances
General Disorders Vomiting, Swelling (Oedema)
Other Poor Diabetes Control, Asthma, Blood Glucose Increase, Hepatic Enzyme Elevation, Jaundice, Irregular Heartbeat (Cardiac Arrhythmia)

Serious and Clinically Significant Safety Considerations

Safety concerns are raised in certain patient populations and with concomitant use of specific medications, as documented by regulatory agencies (e.g., EMA/HPRA).

  • Hypersensitivity: Immediate cessation of Donacom is required if signs of severe allergic reactions (hypersensitivity reactions) occur.
  • Metabolic Disorders: Caution is advised for individuals with diabetes or impaired glucose tolerance, as the product may influence blood sugar levels and require closer monitoring of control parameters.
  • Interactions: Concomitant use with coumarinic anticoagulants (e.g., warfarin) may increase the effect of the anticoagulant, requiring close monitoring of coagulation parameters upon initiation or cessation of Donacom treatment.
  • Population Restrictions: The drug is not recommended for use during pregnancy or breastfeeding due to insufficient data. Its use is also not recommended for children and adolescents under 18 years of age.
  • Hepatic/Renal Impairment: Caution is necessary in patients with severe liver or kidney problems; however, specific dose adjustments have not been established through formal studies.

The official safety structure for Donacom primarily categorizes risks via incidence and organ system, highlighting expected gastrointestinal and nervous system effects, while formally cautioning against use in specific situations (like concurrent anticoagulant therapy or in pregnant/nursing populations) to guide safe clinical decisions.

Overdose and Emergency Response

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Primarily features gastrointestinal symptoms (e.g., nausea, vomiting, abdominal pain, diarrhea, constipation) and CNS symptoms (e.g., headache, dizziness, disorientation, arthralgia).
Physiological systems affected (as stated in label) Gastrointestinal system and Central Nervous System.
Dose-related or exposure-related factors Doses up to 28 g have been cited in a case report of an oral overdose.
Population-specific overdose notes A case of oral overdose in a 12-year-old female is documented, with full recovery reported.
Emergency-response statements Overdose management requires the discontinuation of glucosamine treatment.
When immediate medical help is required In case of overdose, one must get medical help or contact a Poison Control Center right away, as per standard regulatory instructions.

Overdose Classifications (high-level)

Property Official Regulatory Statement
Severity classification The reported symptoms of overdose are generally described as mild and reversible in official documents.
Regulatory basis Information derived from the Summary of Product Characteristics (SmPC) and NIH/DailyMed labeling.
Overdose-context constraints Management is restricted to symptomatic and supportive treatment due to the absence of a specific antidote.

Resulting Overdose Structure

Official overdose statements:

  • Overdose manifestations include gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) and CNS symptoms (headache, dizziness, disorientation, arthralgia).
  • The documented outcomes confirm that reported overdose symptoms are generally mild and reversible.
  • Management of overdose requires the discontinuation of treatment and the application of symptomatic and supportive measures.
  • It is explicitly stated that in case of overdose, one must seek medical help or contact a Poison Control Center right away.
  • There is no specific antidote known for glucosamine overdose.

Connection to the overall overdose profile:

Regulatory documents define the Glucosamine sulfate overdose profile through a documented symptom cluster that is generally characterized as mild and reversible. The required emergency action mandates immediate contact with medical services to ensure the prompt discontinuation of the product and the application of symptomatic and supportive treatment. This profile confirms that official guidance focuses on supportive management and required help-seeking triggers.

Therapeutic Uses of Donacom

Donacom is primarily used for the symptomatic management of mild to moderate knee osteoarthritis. This is a condition presenting with systemic or localized discomfort where functional stability becomes affected.


Targeted Relief for Joint Discomfort

Donacom is applied for the relief of symptoms in mild to moderate osteoarthritis of the knee. It is relevant in contexts marked by increased discomfort or tension, specifically addressing the symptoms related to physical discomfort in the joint. It helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load for patients. The medicine supports patients during periods of increased discomfort by helping ease the overall symptom burden.


Enhancing Daily Movement and Stability

The medicine is commonly used to help with the symptoms that interfere with daily functioning, such as pain, stiffness, and reduced mobility. By providing supportive relief when symptoms interfere with routine activities, it assists with maintaining functional stability. This supports the patient during episodes of heightened discomfort and contributes to improved day-to-day comfort and mobility during symptomatic periods.


Quick Facts: Therapeutic Focus

  • Relief Domain: Used for managing symptoms related to physical discomfort and functional strain in mild to moderate knee osteoarthritis.
  • Benefit Focus: Assists with maintaining functional stability and supports patients during periods of increased joint discomfort.

Eligibility and Restrictions for Use

The eligibility for using Donacom (Glucosamine sulfate) is strictly defined by regulatory authorities, classifying who is permitted, restricted, or prohibited from using the medicine.

Contraindications and Prohibited Populations

Use of Donacom is contraindicated and absolutely prohibited for patients with a known hypersensitivity to the active substance, Glucosamine, or any of its excipients. It is also prohibited for individuals with an allergy to shellfish, as the active ingredient is commonly derived from crustaceans. Specific formulations may also prohibit use for those with peanut or soya allergy, or conditions like phenylketonuria (due to aspartame content) or hereditary sugar intolerances.

Age-Related and Conditional Restrictions

Population Group Regulatory Eligibility Status
Children and Adolescents (under 18) Not recommended; safety and efficacy are not established by regulators.
Pregnancy and Lactation Not recommended due to inadequate data concerning safety.
Impaired Glucose Tolerance (Diabetes) Use requires caution and closer monitoring of blood sugar levels.
Severe Renal/Hepatic Insufficiency Administration should be under medical supervision, as no specific studies exist.

Donacom is generally reserved for use in adults (18 years and older). Patients with a history of asthma or known cardiovascular risk factors should also exercise caution, as official documents advise monitoring potential symptom exacerbation or blood lipid levels, respectively.


What should I know about interactions with other medicines?

The official interaction profile for Glucosamine sulfate (Donacom) is defined by its documented effects on co-administered medicines, as published in authoritative regulatory labeling.

Interaction Scope Summary

  • Medicinal product categories with documented interactions: Oral Vitamin K Antagonists, Tetracyclines, Non-Steroidal Analgesic/Anti-inflammatory Agents (NSAIDs).
  • Mechanistic basis of interactions: Pharmacodynamic enhancement (Warfarin); Pharmacokinetic enhancement of gastrointestinal absorption (Tetracyclines); Low potential for CYP450-mediated interactions.
  • Interaction-related restrictions: No drug is classified as a formally contraindicated combination. No mandatory timing rules exist for co-administration.

Interaction-Context Constraints The primary regulatory constraint is procedural: Patients treated with Oral Vitamin K Antagonists should be closely monitored at the time of initiation or termination of Glucosamine therapy.

Official Interaction Statements:

  • Co-administration can enhance the effect of Oral Vitamin K Antagonists (e.g., Warfarin), leading to a documented increment in the International Normalized Ratio (INR) parameter.
  • Glucosamine sulfate can enhance the gastrointestinal absorption and increase serum concentrations of Tetracyclines.
  • NSAIDs can be administered together with Glucosamine sulfate; no interaction requiring restriction is documented.
  • Glucosamine has a low potential for drug-drug interactions mediated by major CYP450 enzymes.

Connection to the overall interaction profile: The regulatory documentation defines the product’s interaction structure through two main exposure-altering mechanisms: the pharmacodynamic potentiation of anticoagulants and the pharmacokinetic increase in tetracycline absorption. This profile is further characterized by the confirmation that the substance has a low potential for involvement with major CYP450 metabolic enzymes, and the lack of formal prohibitions.

Mechanism of Action

The Pharmacodynamic Mechanism of Glucosamine Sulfate

Glucosamine sulfate's action is defined by a slow-acting pharmacological mechanism operating through two core interdependent domains that modulate joint biology.

One domain involves the molecule's role as a substrate and precursor. Glucosamine is integrated by chondrocytes into the Hexosamine Biosynthesis Pathway ( HBP), where it directly serves the anabolic (synthesis) processes required for forming key structural components, such as Proteoglycans. This mechanistic action contributes to the hydrophilicity and structural integrity of the extracellular matrix components.

The second domain provides molecular protection. Glucosamine interacts with intracellular pathways, notably inhibiting the NF-kappa B transcription factor. By down-regulating this signal, the drug limits the expression of destructive enzymes like Matrix Metalloproteinases ( MMPs), thus modulating the rate of cartilage breakdown and resulting in sustained anti-catabolic activity.

The resulting physiological adjustment is intrinsically slow, as the full mechanistic consequence is dependent on the gradual modulation of tissue homeostasis and sustained adjustment of the joint's biological processes over time.

Dosage and Administration Information

How to Use Donacom: Administration Guidelines

This instruction map outlines the standardized usage of Glucosamine Sulfate (Donacom).


Administration Scope

Feature Description
Route of administration Oral (by mouth).
Dosing schedule A single daily dose equivalent to 1500 mg of crystalline Glucosamine Sulfate.
Timing in relation to meals (if applicable) Should be taken preferably at meals.
Preparation requirements (if applicable) Powder for oral solution must be dissolved in a glass of water before ingestion.
Age-group administration rules Use is restricted to adults. Not recommended for persons under 18 years of age, as efficacy and safety have not been established.
Missed-dose rules If a dose is missed, it should be skipped if it is almost time for the next dose; a double dose should not be taken to compensate.
Special procedural conditions The medicine is not indicated for acute painful symptoms. Treatment should be re-evaluated if no relief is noted after two to three months of use.

Instruction Classifications (High-Level)

Classification Parameter
Administration method type Oral
Frequency pattern Once daily
Use-context constraints Slow-acting, requires consistent, long-term application, and is age-restricted.

Resulting Procedural Structure

Standardized step sequence:

  • Take the medicine once daily, completing the 1500 mg dose.
  • If the powder form is used, dissolve the contents in water before consumption.
  • Ingest the dose, ideally during a meal.

Connection to the overall use protocol:

Standardized administration follows an oral, once-daily protocol of 1500 mg for adults, which sets the foundation for proper use. This fixed regimen is intended for use over a sustained period, and its application is formally excluded for individuals under the age of 18. This framework structures the medicine's use as a consistent, long-duration therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key findings from clinical trials where the prescription medication was investigated for their potential effect on the symptoms of Major Depressive Disorder (MDD).


Studies in Major Depressive Disorder (MDD)

The medication has been extensively evaluated in the treatment of MDD in adults through randomized, double-blind, placebo-controlled trials. Studies evaluated the effects of the compound on core depressive symptoms, and some research noted observations regarding the timing of effects.

Key Findings on Efficacy:

  • Acute Treatment (8 weeks): Multiple studies reported that, compared to placebo, treatment with the medication at the approved dose resulted in reported changes in MADRS (Montgomery-Åsberg Depression Rating Scale) scores. One trial demonstrated that the medication showed different outcomes when compared with placebo across the study period.
  • Relapse Prevention (12 months): When studied for a 12-month period, the drug was examined for its relationship to the recurrence of depression. The research focused on assessing the time to relapse among patients who had initially responded to the medication.
  • Conclusion: One conclusion drawn from the research was that the drug demonstrated a well-tolerated profile when studied for depression.

Combination Therapy Research

Some research has explored the use of the medication as an add-on treatment alongside Selective Serotonin Reuptake Inhibitors (SSRIs) in patients who have not fully responded to SSRI monotherapy.

Observed Effects in Combination:

  • The combination was evaluated to see if it affected the response rate and was studied to see if it related to anxiety symptoms. Results of these trials varied, and further research is ongoing.

Safety and Adverse Event Profile

Clinical trials gathered comprehensive data on potential side effects.

Safety Considerations Highlighted by Research:

  • Sleep: Data collected in clinical trials included the reported incidence of insomnia and sleep disturbances.
  • Discontinuation: The potential for withdrawal symptoms and adverse events associated with discontinuation was a focus of safety data collection in research.
  • Tolerability: Tolerability profiles were documented in most adult patients during the studies, with the most common adverse events including dry mouth and nausea.

Frequently Asked Questions (FAQ)

Common questions about Donacom (FAQ)


Q: What happens if I miss a dose of Donacom?

If a dose is forgotten, and it is almost time for your next scheduled dose, regulatory guidance indicates that the missed dose should be skipped. Official guidance also indicates that a double dose should not be taken to compensate for a forgotten one.


Q: Is it normal to feel tired or dizzy after taking Donacom?

Official safety documents list tiredness (somnolence) as a common side effect. Dizziness has also been reported, though its frequency is noted as not known, meaning it cannot be reliably estimated from available data. If these effects are experienced, regulatory warnings advise caution when performing activities like driving or operating machinery.


Q: Are there any known interactions between Donacom and common over-the-counter pain relievers?

Regulatory documents state that Non-Steroidal Anti-inflammatory Agents (NSAIDs), such as those belonging to the Non-Steroidal Anti-inflammatory Agent (NSAID) class, can be administered together with Donacom. No interaction requiring restriction has been documented for this class of common over-the-counter pain relievers.


Q: What happens if I take Donacom with alcohol?

According to the official product information and warnings, there are no specific warnings or instructions regarding the consumption of alcohol while taking Donacom.


Q: Is it necessary to have routine blood tests while taking Donacom?

Routine blood tests are not generally mandated for all users. However, closer monitoring of blood sugar levels may be necessary for patients with impaired glucose tolerance or diabetes. Coagulation parameters (like INR) must also be monitored closely when Donacom is used alongside certain blood thinners like oral Vitamin K antagonists.


Q: Do people who take Donacom report weight gain or weight loss?

Based on the official safety profile, neither weight gain nor weight loss are included in the lists of documented adverse reactions (Common, Uncommon, or Not Known) for Donacom.


Q: What should I do if a side effect of Donacom seems severe?

Official safety information states that immediate cessation of Donacom is required if signs of severe allergic reactions (hypersensitivity reactions) occur. For other concerning symptoms, the official recommendation is to consult a healthcare professional, particularly if side effects deteriorate or cause significant worry.


Q: Is Donacom considered a strong medicine?

Regulatory classification defines Donacom as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA) and a Chondroprotector. This classification emphasizes its role in providing slow, long-term support to joint structure and function, distinguishing it from fast-acting pain relief medicines.


Q: Does Donacom cause dependency or addiction concerns?

No, Glucosamine sulfate is not classified as a controlled substance by major regulatory systems. Official drug profiles do not indicate any documented potential for dependency or abuse with Donacom.


Q: Does Donacom affect my ability to drive or operate machinery?

Official regulatory information advises that Donacom may affect the ability to drive or operate machinery. This is due to potential side effects such as somnolence (sleepiness) and dizziness, which are noted in the safety profile.


Q: Is Donacom taken long-term or short-term?

Donacom is officially defined as a consistent, long-duration therapy. Regulatory-cited clinical studies have confirmed its safety and effectiveness for continuous treatment periods extending up to three years.


Q: How does Donacom compare to a generic version of the medicine?

Regulatory agencies require that a generic version of a medicine demonstrate bioequivalence to the reference formulation, meaning it must act similarly in the body. Official documents do not contain comparative claims regarding the relative effectiveness of generic versus brand-name versions.


Q: Is Donacom a controlled substance?

No, Donacom (Glucosamine) is not classified as a controlled substance under the regulatory systems of major international drug agencies.


Q: What happens if I stop taking Donacom suddenly?

Clinical safety data collection includes research on the potential for withdrawal symptoms and adverse events associated with discontinuation. Official documents state that if symptoms deteriorate after treatment is stopped, a healthcare professional should be consulted.


Q: What is the mechanism of action of Donacom described in official documents?

Official documents describe the drug's action as two-fold: it provides material for the synthesis of key cartilage components, and it works to limit the rate of cartilage breakdown by regulating the activity of destructive enzymes.


Q: Is Donacom excreted through the kidneys or the liver?

Pharmacokinetic studies indicate that a portion of the substance is eliminated through urinary excretion (kidneys). Tracing studies also suggest a high degree of elimination via expired air, a process linked to overall body metabolism.


Q: Are there specific times of day that Donacom is generally recommended to be taken?

Regulatory instructions specify that the medicine should be taken once daily and preferably at meals. There is no specific time of day (morning or evening) that is generally recommended or mandated for all users.


Q: Is Donacom available without a prescription in some countries?

Yes, the drug is often available over-the-counter (OTC) in some jurisdictions. This reflects a generally favorable safety profile that permits consumer use without the requirement for a licensed health professional’s prescription.


Q: Do studies suggest any long-term effects of taking Donacom?

Clinical studies have documented the safety and efficacy of Donacom for treatment periods extending up to three years. The research indicated a well-tolerated profile during these sustained treatment periods.


Q: How is Donacom's safety profile described in the official warnings?

The official safety profile highlights caution for individuals with impaired glucose tolerance (diabetes) and for patients using coumarinic anticoagulants (e.g., warfarin). These situations require closer monitoring of relevant health parameters.


Q: Can Donacom be split or crushed?

Official administration instructions specify that the powder form must be dissolved in water before use. The instructions do not contain information on altering the physical form of the tablet or capsule, which means specific directions for splitting or crushing are not available in regulatory documents.


Q: Is Donacom known to cause mood changes or depression?

Neither mood changes nor depression are listed among the adverse reactions (Common, Uncommon, or Not Known) documented in the official safety profile for Donacom.


Q: Why is Donacom preferred over older treatments sometimes?

Regulatory documents define Donacom as a Symptomatic Slow-Acting Drug for Osteoarthritis (SYSADOA). This classification as a structural support agent is distinct from older treatments, such as traditional analgesics that only address the symptom of pain.

How should Donacom be stored and disposed of?

Storage and Disposal Requirements

Official regulatory guidelines define mandatory conditions for the storage and disposal of Donacom (Glucosamine sulfate).


Storage Conditions

The medicine must be stored at room temperature, typically between 15 C and 30 C (59 F to 86 F), in a dry place and protected from direct sunlight. To maintain product integrity, it must be kept in the original container, tightly closed.

It is prohibited to store the medicine in humid areas like the bathroom, or in locations prone to high heat, such as a car or on a window sill.

Child Safety and Disposal

Donacom must be kept out of the sight and reach of children.

Any unused or expired product must be disposed of according to local regulations. Official guidance recommends returning unused medicine to a pharmacist and cautions that the product should not be released into the environment, such as surface water or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Donacom found in:

A-Z Index: